By Sherri Oslick --
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
Codon Devices, Inc. v. febit Biotech GmbH et. al.
1:07-cv-01177; filed June 29, 2007 in the District Court of the District of Columbia
Declaratory judgment of non-infringement, invalidity, and unenforceability of U.S. Patent No. 6,586,211 ("Method for Producing Polymers," issued July 1, 2003) based on Codon Devices' operation in the area of synthetic gene manufacturing. View the complaint here.
Purdue Pharma Products LP et. al. v. Par Pharmaceutical Inc. et. al.
1:07-cv-00414; filed June 28, 2007 in the District Court of Delaware
Infringement of U.S. Patent No. 6,254,887 ("Controlled Release Tramadol," issued July 3, 2001) following a paragraph IV certification as part of Par's filing of an ANDA to manufacture a generic version of plaintiffs' Ultram® ER (tramadol hydrochloride, used to treat moderate to moderately severe chronic pain). View the complaint here. As reported here, plaintiffs have previously asserted this patent against Par Pharmaceutical; the present complaint includes an additional dosage included in Par's ANDA.
Daiichi Sankyo Company, Ltd. et. al. v. Mylan Pharmaceuticals Inc. et. al.
2:07-cv-03039; filed June 22, 2007 in the District Court of New Jersey
Infringement of U.S. Patent No. 5,616,599 ("Angiotensin II Antagosist 1-Biphenylmethylimidazole Compounds and Their Therapeutic Use," issued April 1, 1997) following a paragraph IV certification as part of Mylan's filing of an ANDA to manufacture a generic version of plaintiffs' Benicar HCT® (olmesartan medoxomil and hydrochlorothiazide, used to treat hypertension). View the complaint here.
Comments